Industry Organizations Assist Pharma During the Pandemic and Beyond

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume 2021 eBook
Issue 3
Pages: 42-45

Pharmaceutical Technology checked in with AAPS and IPEC-Americas to get an update on how the organizations are navigating the pandemic and planning for the future.

LEOWOLFERT - STOCK.ADOBE.COM

LEOWOLFERT - STOCK.ADOBE.COM

Pharmaceutical development, manufacturing, and quality efforts are often advanced by the work of industry associations and members through conferences, training sessions, publications, and working groups. These efforts continued during the past 18 months, despite restrictions posed by the COVID-19 pandemic. The American Association of Pharmaceutical Scientists (AAPS) and the International Pharmaceutical Excipients Council of the Americas (IPEC-Americas) shared recent activities and industry contributions with Pharmaceutical Technology.Read in this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.

Read in this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 42-45

Citation

When referring to this article, please cite it as PharmTech Editors, “Industry Organizations Assist Pharma During the Pandemic and Beyond,” Pharmaceutical Technology’s Regulatory Sourcebook eBook (September 2021).

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development